HEIDELBERG, Germany, July 28, 2015 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq:AFMD) today announced that on August 4, 2015, the Company will release its financial results for the quarter ended June 30, 2015. The Company's management team will host a conference call to discuss the Company's financial results and recent corporate developments on Tuesday, August 4, 2015 at 8:30 a.m. EST. The call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code 6872210.
|Local - Amsterdam, the Netherlands:||+31 (0) 20 721 9158|
|Local -- Copenhagen, Denmark:||+4532 71 16 58|
|Local – Frankfurt, Germany:||+49 (0) 69 2222 10628|
|Local - Geneva, Switzerland:||+41 (0) 22 567 5432|
|Local - London, U.K.:||+44 (0) 20 3427 1901|
|Local - New York City, U.S.A.:||+1 212 444 0481|
|Local - Paris, France:||+33 (0) 1 70 48 01 66|
An audio webcast of the conference call can be accessed in the "Events" section on the "Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the webcast will be available on Affimed's website shortly after the conclusion of the call and will be archived on the Affimed website for 30 days following the call.
Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed's product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body's own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called natural killer cells, or NK-cells, and T-cells. Affimed's proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells.
Anca Alexandru or Gretchen Schweitzer
MacDougall Biomedical Communications
Phone: +49 89 2424 3494 or
+49 163 613 3359